A Phase 3 Study of PTC923 in Subjects with Phenylketonuria

• Research type

  Research Study

• Full title

  A Phase 3 Study of PTC923 in Subjects with Phenylketonuria

• IRAS ID

  1004978

• Contact name

  Kim Ingalls

• Contact email

  Medinfo@ptcbio.com

• Sponsor organisation

  PTC Therapeutics, Inc.

• Eudract number

  2021-000474-29

• Clinicaltrials.gov Identifier

  NCT05099640

• Research summary

  A Phase 3 Study of PTC923 in Subjects with Phenylketonuria (PKU). PKU is a rare inherited disorder that causes an amino acid called phenylalanine to build up in the body when protein is eaten.
  The summary results are available under the following link: https://clinicaltrials.gov/study/NCT05099640?tab=results
  Upon request for the summary of results, the investigator will refer the trial participant to search about the study on this link: https://clinicaltrials.gov/study/NCT05099640?tab=results . Principal investigators will also be available to address questions that the subjects may raise.

• REC name

  East Midlands - Leicester Central Research Ethics Committee

• REC reference

  22/EM/0077

• Date of REC Opinion

  6 Jun 2022

• REC opinion

  Further Information Favourable Opinion